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Successful Phase III trials with Poly-ADPribose (PARP) inhibitors will have 
implications for stratified cancer therapy. In the current issue, Knezevic et al 
demonstrate that the existing collection of PARP inhibitors each display 
distinctive protein interaction profiles, reaching beyond their intended 
therapeutic target, with implications for metabolic and other disease.  
    
The contest to provide efficacious and tolerable inhibition of Poly-ADPribose-
transferases (PARPs) within the oncology setting is gaining momentum. PARP 
inhibitors, such as olaparib and veliparib, are either FDA approved for monotherapy 
against breast cancer or are currently in Phase III trials. However, PARP inhibitors 
may also be useful in the fight against other cancers including those affecting the 
ovary and prostate, since they block DNA repair to induce synthetic lethality in 
rapidly-dividing tumor cells. Just as not all cancer cells are equal, the same can be 
said it seems for PARP inhibitors. On Pages XXX-XXX of this issue, Knezevic et al 
(1) demonstrate that PARP inhibitors display additional effects beyond their simple 
blockade of PARP. By hitting secondary protein targets in a range of organelles, 
PARP inhibitors may provoke metabolic responses, influencing a wide range of 
homeostatic cell functions and potentially whole body metabolism (Figure 1).  
First identified in 1963 (2) PARP enzymes were largely overlooked until the turn of 
the last century when their potential value in the treatment of BRCA1/2 breast and 
prostate cancers emerged (3). Upon DNA damage, PARPs catalyze ADP-ribose 
transfer to nuclear proteins, using nicotinamide adenine dinucleotide (NAD+) as a 
substrate. This highlights areas of damaged DNA, leading to recruitment of DNA 
repair complexes vital for sustaining cell viability. 
PARP inhibitors represent a class of chemotherapeutics derived from nicotinamide 
analogues, the building blocks for NAD+, which in addition to DNA repair is also 
involved in hundreds of biochemical reactions as a co-enzyme. Thus, highly mobile 
small molecules with nicotinamide binding capacity, such as the emerging PARP 
inhibitors, may exhibit a broad range of effects and interactions, each one 
personalised and mediated by their alternative chemistries. Perhaps unsurprisingly, 
PARP inhibitors  have shown variable  responses in clinical trials, with some being 
more effective than others depending on the breast cancer subtype (often referred to 
as ‘BRCAness’). 
Although PARP inhibitors share similar efficacy towards PARP1/2, there is clear 
disparity between their effects upon cell viability and sensitivity to DNA damage. 
Existing methodologies such as in vitro shift assays have shown limited ability to 
derive information on novel PARP inhibitor-protein interactions. To truly get to the 
bottom of these in vivo observations, and inform human therapeutic use, Knezevic et 
al have employed unbiased LC-MS/MS based proteomic approaches to capture a 
global picture of the ‘PARP inhibitor interactome’ for each of the main inhibitors 
(niraparib, olaparib, rucaparib and veliparib). Through peptide analysis, they 
identified in excess of 1,200 proteins as potential PARP inhibitor binding partners. 
Future utilizsation of this methodology may reveal the components of PARP multi-
protein complex formation in differing models of oncogenic progression. 
Importantly, these interactomes provide unique insight into the divergent effects of 
the PARP inhibitors. Rucaparib exemplifies PARPi interaction diversity by binding the 
endoplasmic reticulum (ER) luminal NADP+ dependent Hexose-6-Phosphate 
Dehydrogenase (H6PDH) and the cytoplasmic NAD+ dependent Inosine-5’-
monophosphate dehydrogenase 2 (IMPDH2). Indeed, IMPDH2 was bound by all four 
PARP inhibitors examined, whereas H6PDH bound only one. Along similar lines, 
niraparib binds the mitochondrial enzyme ferrochelatase (FECH) and deoxycytidine 
kinase (DCK), a nuclear enzyme important for guanine synthesis. Indeed, the 
interaction of niraparib with DCK is the first identification of a kinase being inhibited 
by a PARPi.   
The interaction of rucaparib with H6PDH is of particular relevance to both cancer and 
metabolism research. H6PDH has been shown to be an enzyme intimately linked to 
ER redox regulation and glucocorticoid metabolism and activation as part of an ER-
specific pentose phosphate pathway. Mice lacking H6PDH display abnormalities in 
glucocorticoid metabolism in many tissues, as well as a progressive skeletal 
myopathy that is associated with the induction of ER stress, unfolded protein 
responses and apoptotic signals in glycolytic type IIb fibres (4,5). To date, the 
mechanistic link between sarcoplasmic reticulum stress and H6PDH has not been 
fully reconciled, but insight can be garnered through the present studies. The take 
home message from this is that H6PDH inhibition may be a useful target to limit 
cellular proliferation, as silencing H6PDH in CAL-51 breast cancer cells can induce 
apoptosis, further sensitizing cells to PARP inhibition. Any potential side effects 
would be offset by the benefits of sensitization to the PARPi. 
Clearly, there is a propensity for PARP inhibitors to interact with a range of 
NAD(P)(H) binding proteins. Indeed, PARP inhibition could have the effect of 
influencing cellular NAD+ and ATP levels, impacting upon mitochondrial oxidative 
phosphorylation and whole body energy metabolism, though what this means for the 
cancer cell versus the non-cancer cell are unclear (Figure 1). PARP inhibitors do not 
directly interact with NAD+-dependent sirtuins, important sensors of a cells metabolic 
set point, that when activated by NAD+ can augment energy metabolism through 
post-translational protein deacetylation and activation of adaptive transcriptional 
programs. However, this does not necessarily preclude an indirect effect of PARP 
inhibitors on sirtuin expression and activity. Indeed, PARPs have a high affinity for 
NAD+ and modulation of their activity may plausibly influence sirtuin access to the 
co-enzyme. IN support of this previous by Bai et al demonstrated that PARP 
inhibition increases NAD+ availability, enhancing sirtuin 1 activity and PGC1a-
mediated mitochondrial biogenesis (6). Notably, different members of the sirtuin 
family display both oncogenic and tumor suppressive features. By virtue of sparing 
NAD+, PPAR inhibitors could therefore have far-reaching effects on cell function, 
extending beyond each PARP inhibitor-interactome and into organelles beyond the 
nucleus.   
The identification of extra-nuclear interactions creates new opportunities for human 
therapy with the PARP inhibitors, but also raises a new set of questions regarding 
the exact mechanisms underlying their activity, particularly when used as anti-cancer 
drugs. While specificity is a desirable attribute, many drugs demonstrate off-target 
effects that can either be useful or harmful. Drug safety and efficacy requires that we 
first understand molecular targets and any impact upon the cellular compartment 
they are localized to. Indeed, the enzymes shown here to interact with PARP 
inhibitors may prove to be fruitful future treatment targets for other cancers and 
metabolic diseases. Thus, the present work establishes PARP inhibitor-specific 
interactomes. These require detailed scrutiny when considering the utility of these 
PARP inhibitors in ‘targeted’ treatment of cancer and other diseases. 
 
 
 
 
 
 
 
 
  
  
 
Figure 1. PARP inhibition staying on target? : PARP inhibition may have far 
reaching effects. A) Inhibition of PARPs increases cellular NAD+ and ATP, resulting 
in changes in glycolysis, lipolytic and TCA cycle rates. B) The PARP inhibitors 
rucaparib and niraparib have their own individual interactomes with proteins outside 
the nucleus.    
 
 
 
 
 
  
Acknowledgements 
We would like to extend our gratitude to Professor David Hodson, University of 
Birmingham, for critical evaluation and enhancement of our manuscript. 
 
 
References 
(1) Knezevic et al. Cell Chem Biol  
(2) Chambon et al. Biochem Biophys Res Commun. 1963 Apr 2;11:39-43. 
(3) Farmer et al. Nature V.434 April 2005 
(4) Lavery et al. JBC 2006  
(5) Semjonous et al.  Endocrinology 2011 
(6) Bai et al. Cell Metab 2011 April 6 461-468 
 
